HIV 1 News and Research

RSS

Rome Statement for an HIV Cure calls for accelerated research

Members of the Advisory Board for a Global Scientific Strategy "Towards an HIV Cure" today launched the Rome Statement for an HIV Cure calling for an acceleration of HIV cure research. The announcement was made at the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) currently being held in Rome

18 Jul 2011

Partners can help advance global HIV/AIDS fight

In a post on the State Department's "DipNote" blog, Ambassador Eric Goosby, the U.S. global AIDS coordinator, highlights recent findings that help reduce the risk of HIV transmission. He writes, "In order for us to fulfill the promise of these findings, we will continue to foster shared responsibility among all parties.

18 Jul 2011

ISENTRESS demonstrates comparable efficacy to efavirenz in treatment-naïve adult HIV-1 patients

Merck, known as MSD outside the United States and Canada, today announced final results from a Phase II clinical study, extending out to 240 weeks, of its integrase inhibitor ISENTRESS® (raltegravir) Tablets in combination therapy in previously untreated (treatment-naïve) adult HIV-1-infected patients.

18 Jul 2011

SEEK HIV-v vaccine demonstrates 90% reduction in HIV viral load

SEEK, a privately owned biopharmaceutical company specializing in immunology, announces today that it has completed a Phase Ib/II clinical trial of its HIV-v vaccine which demonstrates a one log (approx 90 percent) difference in viral count in HIV-infected people compared with the placebo group, after just a single vaccine injection.

18 Jul 2011

Experimental online tool launched to guide HIV treatment decisions without the need for resistance testing

A new free online service with the potential to help HIV treatment in countries with limited healthcare resources was launched today. The system accurately predicts how patients will respond to different combinations of drugs without the need for expensive tests to read the viral genetic code. Data presented today at the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) demonstrated the accuracy of the system for patients in Romania and South Africa whose treatment was failing (abstract MOPE146).

18 Jul 2011

Study recommends short and simple HIV consent forms

An in-depth review of consent forms provided to volunteers for HIV/AIDS research in the United States and abroad about study procedures, risks and benefits has found that the forms were extremely long and used wording that may have been complex enough to hinder full understanding, according to bioethicists at The Johns Hopkins University.

16 Jul 2011

U.S. will strengthen health work in Haiti

In a post on the AIDS.gov blog, Ambassador Eric Goosby, U.S. global AIDS coordinator, writes about a recent visit to Haiti and gives an update on U.S. work with Haiti.

16 Jul 2011

Shah congratulates researchers on PrEP findings

In statement released Thursday, USAID Administrator Rajiv Shah said, "I congratulate the Partners PrEP and CDC TDF2 teams on their study findings demonstrating that PrEP (pre-exposure prophylaxis) - and HIV medication when taken orally, once a day - is highly effective in preventing HIV in heterosexual men and women.

16 Jul 2011

Lancet issue dedicated to HIV/AIDS ahead of IAS conference

The current issue of the Lancet is dedicated to HIV/AIDS, a theme meant to coincide with the sixth International AIDS Society (IAS) conference on HIV pathogenesis, treatment and prevention taking place in Rome, Italy, July 17-20, according to a Lancet article.

16 Jul 2011

Inovio reports strong immune responses with VGX-3100 vaccine for cervical dysplasia and cancer

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, has reported data demonstrating long-term durability of T cell immune responses of up to over two years (at the latest time measured) in 7 of 8 evaluated patients following a fourth vaccination of VGX-3100, its investigational SynCon® DNA vaccine for treating cervical dysplasia and cancer caused by human papillomavirus (HPV) that is delivered using intramuscular electroporation.

15 Jul 2011

Scientific American presents slide show on MTCT prevention

UNICEF's goal of eliminating mother-to-child HIV transmission by 2015 is "ambitious ... but not impossible," Scientific American reports.

15 Jul 2011

Women with current major depression more likely to use crack

Women who are clinically depressed at the time they enter drug court have a substantially higher risk of using crack cocaine within four months, according to a new study.

15 Jul 2011

New survey on access to HIV prevention and treatment among MSM

A new survey (.pdf) of more than 5,000 men who have sex with men (MSM), conducted by the Global Forum on MSM & HIV (MSMGF), "has shown that less than half of MSM around the world have easy access to lifesaving HIV prevention and treatment services," according to an MSMGF press release.

14 Jul 2011

Study finds structural determinants of adolescent girls' vulnerability to HIV

A new study led by researchers at the Johns Hopkins Bloomberg School of Public Health shows that community members correlate an increase in HIV vulnerability among adolescent girls with weak structural support systems.

14 Jul 2011

Two new studies support use of PrEP for HIV prevention among heterosexual men and women

"Two new studies done in three African countries have shown for the first time that AIDS drugs taken daily can cut by more than half a person's chance of becoming infected with HIV through heterosexual intercourse," the Washington Post reports.

14 Jul 2011

Studies show AIDS drugs can prevent heterosexuals from acquiring HIV

Two new studies released early Wednesday show that AIDS drugs can prevent heterosexuals from acquiring HIV, adding to a growing number of new methods to slow the spread of the virus world-wide.

14 Jul 2011

Malaria prevention project using dirty sock odor awarded Grand Challenges grant

The odor of dirty socks can be used to attract mosquitoes and kill them before they're able to spread malaria, Fredros Okumu of the Ifakara Health Institute in Tanzania said on Wednesday, Agence France-Presse reports.

14 Jul 2011

Positive data from Inovio's VGX-3400X Phase I study against H5N1 influenza

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation.

14 Jul 2011

Five-year research initiative to cure HIV disease

A team of AIDS experts at Johns Hopkins and other institutions have embarked on a joint five-year research initiative to cure HIV disease by finding ways to completely purge the virus from the body in people already successfully suppressing the virus with antiretroviral drug therapy.

14 Jul 2011

Foreign Policy examines HIV epidemic in Swaziland

Foreign Policy examines the HIV epidemic in Swaziland, where nearly one-fifth of residents are infected. Because of the country's high per capita infection rate, one might expect HIV to slap you in the face. But there are no buildings collapsed by an HIV earthquake, no towns flooded by an HIV tsunami.

14 Jul 2011